Tony Robbins Won't Stop Talking About NMN. Here's the Actual Science.

Tony Robbins has spent the last few years telling anyone who will listen that aging is a disease. His pitch: NMN (nicotinamide mononucleotide) is part of how he's fighting it. Clips from his sit-down with Logan Paul on the Impaulsive podcast are recirculating again right now. In it, Robbins claims a chronological age of 60 and a biological age of 51. He also tells the story of biochemist Dr. David Sinclair's father, who Robbins says regained the ability to walk and think clearly with NMN and NAD+ support.

While its an amazing story... It's one anecdote, told by a motivational speaker, not a clinician. So we're setting the podcast aside and looking at what's actually been measured in controlled human trials.

What NMN Actually Is

NMN isn't a longevity compound on its own. It's a precursor. It sits in the salvage pathway your body uses to make NAD+ (nicotinamide adenine dinucleotide), a coenzyme required for redox reactions in nearly every cell you have. NAD+ is a co-substrate for sirtuins, the SIRT1 through SIRT7 family of deacetylases. It's required for PARP enzymes involved in DNA repair. It's consumed by CD38. Glycolysis, the TCA cycle, oxidative phosphorylation: none of it runs without NAD+/NADH cycling.

Here's the part Robbins gets right. NAD+ declines with age. That decline is tied to reduced NAMPT activity, the rate-limiting enzyme that converts nicotinamide into NMN, combined with rising NAD+ consumption by PARPs and CD38 as cellular damage accumulates. Lower NAD+ means lower sirtuin activity. Sirtuins run mitochondrial function, nuclear-mitochondrial communication, and cellular stress response. That's why NAD+ decline shows up in the literature as a plausible driver of age-related mitochondrial dysfunction, not just a marker of it.

Supplementing with NMN (or NR, its cousin) is an attempt to push more raw material into that pathway as your own production slows.

What Human Trials Actually Show

Here's where most influencer content stops digging. We didn't.

NAD+ levels go up. Consistently. A 12-week RCT in 36 healthy middle-aged adults at 250 mg/day found NMN significantly raised NAD+ metabolites, well tolerated, zero adverse events. A separate 6-to-12-week trial in older men at the same dose confirmed the same NAD+ increase with a clean safety profile. A larger dose-ranging RCT running 300, 600, and 900 mg/day in 80 participants confirmed the effect scales with dose. Across every trial we found, NMN held a strong safety profile up to 1,200 mg/day with no serious adverse events.

Physical performance: mixed, but leaning positive. A systematic review covering 10 RCTs and 437 patients found generally positive effects on aerobic capacity, though the authors flagged the evidence base as still young. One trial in older adults found NMN maintained walking speed and improved sleep quality (daytime dysfunction and global PSQI scores) over 12 weeks, alongside the expected NAD+ bump. A separate RCT in amateur runners found NMN combined with training improved aerobic capacity in a dose-dependent way across 300/600/1200 mg/day arms over six weeks.

Metabolic outcomes are the weak point. A 2024 meta-analysis of 12 RCTs and 513 participants confirmed NMN reliably raises NAD+ but found no significant improvement in fasting glucose, triglycerides, LDL-C, or HDL-C versus placebo. Worth saying plainly: NMN isn't well-supported as a glucose or lipid intervention in humans yet, whatever the mouse data suggested.

Vascular effects: still inconclusive. One RCT looking at arterial stiffness found a trend toward improvement with NMN. It didn't reach statistical significance.

Where That Leaves You

NMN does the one thing it's mechanistically built to do. It raises blood NAD+ in humans, safely, across multiple independent trials. What it doesn't yet have is strong human evidence for the bigger claims. Robbins' "reversing aging" framing runs well ahead of the data. Sleep quality and walking speed have real, early RCT support. Metabolic markers mostly don't move. Nobody's run a trial long enough to make a lifespan claim in humans, and one story about a friend's father doesn't change that.

That's the real state of the science. Not the podcast-clip version. If you're taking NMN to support NAD+-dependent cellular processes as part of a broader stack, the data backs that. If you're expecting it to reverse aging on its own, the trials aren't there yet.

Sources

1. Yi L, et al. Association between blood NAD levels and blood laboratory parameters at baseline and after NMN supplementation. PubMed, 2025.
2. Igarashi M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood NAD+ levels and alters muscle function in healthy older men. PMC, 2022.
3. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term NMN supplementation: a randomized, double-blind, placebo-controlled trial. PMC, 2023.
4. Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults. PubMed, 2024.
5. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. PMC, 2021.
6. Improved Physical Performance Parameters in Patients Taking NMN: A Systematic Review of Randomized Control Trials. PMC, 2024.
7. Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on RCTs. Nutrition Reviews / Taylor & Francis, 2024.
8. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology, 2021.
9. It takes two to tango: NAD+ and sirtuins in aging/longevity control. npj Aging and Mechanisms of Disease, 2016.
10. NAD+ and sirtuins in aging and disease. Trends in Cell Biology / ScienceDirect, 2014.